JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

Search

Corvus Pharmaceuticals Inc

Uždarymo kaina

7.57 -3.44

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

7.48

Max

7.87

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-23M

-8M

Pelno marža

-13,764.773

Darbuotojai

31

EBITDA

-360K

-10M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+78.12% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-11-12

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

253M

586M

Ankstesnė atidarymo kaina

11.01

Ankstesnė uždarymo kaina

7.57

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

Corvus Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-10-28 23:50; UTC

Karštos akcijos

Stocks to Watch: Caesars, Enphase, Mondelez, Teradyne

2025-10-28 23:25; UTC

Uždarbis

SK Hynix Posts Record Earnings on Continued AI-Chip Demand

2025-10-28 23:18; UTC

Uždarbis

Booking 3Q Sales Rise as U.S. Travel Demand Stabilizes -- Update

2025-10-28 22:20; UTC

Uždarbis

Visa Sales Jump as Consumers Keep Spending -- 2nd Update

2025-10-28 22:13; UTC

Uždarbis

Wal-Mart de Mexico Net Profit Falls in 3Q

2025-10-28 21:38; UTC

Uždarbis

Correction to Visa Sales Jump Article

2025-10-28 21:17; UTC

Uždarbis

OrthoPediatrics Wins FDA Approval for Surgery Plating System; 3Q Revenue Rises

2025-10-28 21:07; UTC

Uždarbis

Visa Sales Jump as Consumers Keep Spending -- Update

2025-10-28 21:02; UTC

Uždarbis

Mondelez Tempers Outlook as Costs Rise

2025-10-28 23:51; UTC

Rinkos pokalbiai

Nikkei May Rise on Easing U.S.-China Tensions -- Market Talk

2025-10-28 23:42; UTC

Rinkos pokalbiai

Gold Edges Lower on Possible Position Adjustments Ahead of FOMC Decision -- Market Talk

2025-10-28 23:02; UTC

Uždarbis

SK Hynix: HBM4 Shipments to Start in 4Q, Ahead of Full-Scale Sales Expansion in 2026

2025-10-28 23:01; UTC

Uždarbis

SK Hynix: Completed Discussions With Key Customers About 2026 HMB Supply

2025-10-28 22:46; UTC

Uždarbis

SK Hynix: Co. Secured Full Customer Demand for Its Entire DRAM and NAND Production for Next Yr >000660.SE

2025-10-28 22:45; UTC

Uždarbis

SK Hynix 3Q Net KRW12.6T >000660.SE

2025-10-28 22:44; UTC

Uždarbis

SK Hynix 3Q Rev KRW24.44T >000660.SE

2025-10-28 22:43; UTC

Uždarbis

SK Hynix 3Q Net Profit Beat FactSet-Compiled Consensus

2025-10-28 22:42; UTC

Uždarbis

SK Hynix 3Q Net KRW12.598T Vs. Net KRW5.753T >000660.SE

2025-10-28 22:40; UTC

Uždarbis

SK Hynix 3Q Rev KRW24.449T Vs. KRW17.573T >000660.SE

2025-10-28 22:40; UTC

Uždarbis

SK Hynix 3Q Oper Pft KRW11.383T Vs. Pft KRW7.030T >000660.SE

2025-10-28 22:22; UTC

Uždarbis

Pharmaron Beijing: Higher Contributions From Clinical-Development Services Supported Results >300759.SZ

2025-10-28 22:22; UTC

Uždarbis

Pharmaron Beijing: Higher Contributions From Laboratory Services Supported Results >300759.SZ

2025-10-28 22:22; UTC

Uždarbis

Pharmaron Beijing 3Q Net CNY439.52M, Up 42.5% on Year >300759.SZ

2025-10-28 22:20; UTC

Uždarbis

Pharmaron Beijing 3Q Rev CNY3.64B, Up 13.4% on Year >300759.SZ

2025-10-28 22:02; UTC

Uždarbis

Review & Preview: Earnings Extravaganza -- Barrons.com

2025-10-28 21:42; UTC

Rinkos pokalbiai
Uždarbis

Global Equities Roundup: Market Talk

2025-10-28 21:42; UTC

Rinkos pokalbiai
Uždarbis

Mondelez Says Cocoa Costs Peaked Heading Into Spooky Season -- Market Talk

2025-10-28 21:20; UTC

Uždarbis

Wal-Mart de Mexico 3Q EBITDA MXN25.27B, Up 3.3% on Year

2025-10-28 21:19; UTC

Uždarbis

Wal-Mart de Mexico 3Q Rev MXN241.52B, Up 4.9% on Year

2025-10-28 21:18; UTC

Uždarbis

Wal-Mart de Mexico 3Q Net MXN11.75B, Down 9.2% on Year

Akcijų palyginimas

Kainos pokytis

Corvus Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

78.12% į viršų

12 mėnesių prognozė

Vidutinis 14 USD  78.12%

Aukščiausias 16 USD

Žemiausias 11 USD

Remiantis 3 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Corvus Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

3 ratings

3

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

3.165 / 3.5827Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bearish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
help-icon Live chat